Preferred therapies for neovascular age-related macular degeneration - PubMed (original) (raw)
Review
Preferred therapies for neovascular age-related macular degeneration
David R Lally et al. Curr Opin Ophthalmol. 2012 May.
Abstract
Purpose of review: This report reviews the current treatment strategies and the most recent clinical trials in the treatment of neovascular age-related macular degeneration.
Recent findings: The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison. Since then, various modified dosing regimens with the aim of lessening the treatment burden associated with monthly injections have been investigated. Additionally, level I evidence now exists for the noninferiority of bevacizumab, as compared to ranibizumab, in the treatment of neovascular age-related macular degeneration (AMD) through 1 year of follow-up. Aflibercept has emerged as a new anti- vascular endothelial growth factor (VEGF) therapy showing encouraging treatment results at 1 year. Novel treatments combined with anti-VEGF agents such as localized radiation are currently being investigated.
Summary: Anti-VEGF monotherapy remains the preferred therapy for the management of neovascular AMD at the present time. Aflibercept is a new, FDA-approved, effective, anti-VEGF agent available for clinical use. Ongoing clinical trials will help determine the optimal dosing regimens for all of these agents, as well as the long-term efficacy and safety of combination therapy modalities.
Similar articles
- Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
Scott AW, Bressler SB. Scott AW, et al. Curr Opin Ophthalmol. 2013 May;24(3):190-6. doi: 10.1097/ICU.0b013e32835fefee. Curr Opin Ophthalmol. 2013. PMID: 23492430 Review. - Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE, Kanadani TM, Pereira FB, Nehemy MB. Veloso CE, et al. Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30. Ophthalmology. 2015. PMID: 26038338 - Preferred therapies for neovascular age-related macular degeneration.
Chiang A, Regillo CD. Chiang A, et al. Curr Opin Ophthalmol. 2011 May;22(3):199-204. doi: 10.1097/ICU.0b013e32834597d9. Curr Opin Ophthalmol. 2011. PMID: 21427571 Review. - Neovascular age-related macular degeneration.
Veritti D, Sarao V, Lanzetta P. Veritti D, et al. Ophthalmologica. 2012;227 Suppl 1:11-20. doi: 10.1159/000337154. Epub 2012 Apr 24. Ophthalmologica. 2012. PMID: 22517121 Review. - The role of Aflibercept in the management of age-related macular degeneration.
Hassan M, Afridi R, Sadiq MA, Soliman MK, Agarwal A, Sepah YJ, Do DV, Nguyen QD. Hassan M, et al. Expert Opin Biol Ther. 2016;16(5):699-709. doi: 10.1517/14712598.2016.1167182. Expert Opin Biol Ther. 2016. PMID: 26982640 Review.
Cited by
- Establishing Liposome-Immobilized Dexamethasone-Releasing PDMS Membrane for the Cultivation of Retinal Pigment Epithelial Cells and Suppression of Neovascularization.
Lin TW, Chien Y, Lin YY, Wang ML, Yarmishyn AA, Yang YP, Hwang DK, Peng CH, Hsu CC, Chen SJ, Chien KH. Lin TW, et al. Int J Mol Sci. 2019 Jan 9;20(2):241. doi: 10.3390/ijms20020241. Int J Mol Sci. 2019. PMID: 30634448 Free PMC article. - The Question of a Role for Statins in Age-Related Macular Degeneration.
Roizenblatt M, Naranjit N, Maia M, Gehlbach PL. Roizenblatt M, et al. Int J Mol Sci. 2018 Nov 21;19(11):3688. doi: 10.3390/ijms19113688. Int J Mol Sci. 2018. PMID: 30469381 Free PMC article. Review. - Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD.
Farnoodian M, Sorenson CM, Sheibani N. Farnoodian M, et al. J Ophthalmic Vis Res. 2018 Oct-Dec;13(4):470-486. doi: 10.4103/jovr.jovr_67_18. J Ophthalmic Vis Res. 2018. PMID: 30479719 Free PMC article. Review. - Cancer prevention by targeting angiogenesis.
Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Albini A, et al. Nat Rev Clin Oncol. 2012 Sep;9(9):498-509. doi: 10.1038/nrclinonc.2012.120. Epub 2012 Jul 31. Nat Rev Clin Oncol. 2012. PMID: 22850752 Review. - Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering.
Fernández-Robredo P, Sancho A, Johnen S, Recalde S, Gama N, Thumann G, Groll J, García-Layana A. Fernández-Robredo P, et al. J Ophthalmol. 2014;2014:510285. doi: 10.1155/2014/510285. Epub 2014 Jan 14. J Ophthalmol. 2014. PMID: 24672707 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials